George Samonis

Summary

Affiliation: University of Crete
Country: Greece

Publications

  1. pmc Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer
    N Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Br J Cancer 106:1917-25. 2012
  2. pmc BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome
    Zacharenia Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece
    PLoS ONE 8:e84604. 2013
  3. pmc Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
    C Papadaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 104:316-23. 2011
  4. pmc Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients
    Zacharenia Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    PLoS ONE 6:e15980. 2011
  5. pmc Favorable clinical course of patients experiencing bevacizumab-induced proteinuria
    Emmanouil Saloustros
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Case Rep Oncol 3:368-71. 2010
  6. pmc Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
    A Daskalaki
    Department of Pathology, University General Hospital of Heraklion, Crete 71110, Greece
    Br J Cancer 101:589-97. 2009
  7. pmc Small cell ovarian cancer in adolescents: report of two cases and review of the literature
    M Rovithi
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 711 10 Heraklion, Crete, Greece
    Case Report Med 2011:749516. 2011
  8. pmc Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
  9. pmc BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome
    Z Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece
    Br J Cancer 102:1762-8. 2010
  10. pmc Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
    N Xenidis
    Department of Medical Oncology, University Hospital of Heraklion, PO Box 1352, 711 10 Heraklion, Crete, Greece
    Br J Cancer 108:549-56. 2013

Collaborators

Detail Information

Publications168 found, 100 shown here

  1. pmc Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer
    N Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Br J Cancer 106:1917-25. 2012
    ..To investigate the clinical relevance of CK-19mRNA-positive circulating tumour cells (CTCs) detected before the initiation of front-line treatment in patients with metastatic breast cancer (MBC)...
  2. pmc BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome
    Zacharenia Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece
    PLoS ONE 8:e84604. 2013
    ..To prospectively evaluate the usefulness of the BRAFV600E mutation detection in daily clinical practice in patients with metastatic Colorectal Cancer (mCRC)...
  3. pmc Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
    C Papadaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 104:316-23. 2011
    ..We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC) patients treated with docetaxel in association with cisplatin or gemcitabine...
  4. pmc Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients
    Zacharenia Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    PLoS ONE 6:e15980. 2011
    ....
  5. pmc Favorable clinical course of patients experiencing bevacizumab-induced proteinuria
    Emmanouil Saloustros
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Case Rep Oncol 3:368-71. 2010
    ..Clinicians should be aware that the development of proteinuria might serve as a surrogate marker of bevacizumab antitumor efficacy and determine the appropriate criteria for withholding this effective anticancer therapy...
  6. pmc Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer
    A Daskalaki
    Department of Pathology, University General Hospital of Heraklion, Crete 71110, Greece
    Br J Cancer 101:589-97. 2009
    ....
  7. pmc Small cell ovarian cancer in adolescents: report of two cases and review of the literature
    M Rovithi
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 711 10 Heraklion, Crete, Greece
    Case Report Med 2011:749516. 2011
    ..Herein, we report two cases of small cell carcinoma of the ovaries along with a review of the relevant literature...
  8. pmc Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
    A Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Br J Cancer 99:923-9. 2008
    ....
  9. pmc BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome
    Z Saridaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece
    Br J Cancer 102:1762-8. 2010
    ..The significance of BRAF mutations, microsatelite instability (MSI) status and cyclin D1 expression in patients with metastatic colorectal cancer (mCRC) was evaluated...
  10. pmc Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
    N Xenidis
    Department of Medical Oncology, University Hospital of Heraklion, PO Box 1352, 711 10 Heraklion, Crete, Greece
    Br J Cancer 108:549-56. 2013
    ..To determine the effect of adjuvant taxane-free and taxane-based chemotherapy regimens on the elimination of circulating tumour cells (CTCs) in patients with early breast cancer...
  11. pmc Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide
    Niki Karachaliou
    Laboratory of Tumour Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    PLoS ONE 8:e74611. 2013
    ..The aim of the study was to evaluate the predictive value of genes involved in the action of cisplatin-etoposide in Small Cell Lung Cancer (SCLC)...
  12. pmc 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
    A G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Br J Cancer 97:1560-6. 2007
    ..The clinical relevance of 'other' EGFR mutation variants remains uncertain and requires further assessment in a prospective study...
  13. pmc A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples
    Lampros Dimitrakopoulos
    Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, 15771, Greece
    BMC Cancer 12:486. 2012
    ..The aim of our study was to develop a Methylation-Sensitive High Resolution Melting Analysis (MS-HRMA) assay for the investigation of CST6 promoter methylation...
  14. doi request reprint Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
    V Georgoulias
    Department of Medical Oncology, University Hospital of Heraklion, and Medical School, University of Crete, Heraklion, Crete, Greece
    Ann Oncol 23:1744-50. 2012
    ..Since the detection of circulating tumor cells (CTCs) which express HER2 is an adverse prognostic factor in early breast cancer patients, we investigated the effect of trastuzumab on patients' clinical outcome...
  15. doi request reprint Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis
    Zoe Giannousi
    Department of Medical Oncology, University General Hospital of Heraklion, Stavrakia and Voutes, Heraklion, 71110, Crete, Greece
    Support Care Cancer 20:1823-9. 2012
    ..The prognostic significance of the recorded parameters was also assessed...
  16. doi request reprint Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study
    N Kentepozidis
    Department of Medical Oncology, 251 Air Force Hospital, 3, P Kanellopoulou Str, 115 25 Athens, Greece
    Cancer Chemother Pharmacol 70:161-8. 2012
    ..To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer...
  17. pmc Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
    J Souglakos
    Hellenic Oncology Research Group HORG, 55 Lomvardou str, Athens 11470, Greece
    Br J Cancer 106:453-9. 2012
    ..To compare the efficacy and safety of CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC)...
  18. pmc Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
    Galatea Kallergi
    Laboratory of Τumor Cell Βiology, University of Crete, Heraklion, Greece
    Breast Cancer Res 13:R59. 2011
    ....
  19. pmc Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients
    Galatea Kallergi
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Voutes, Heraklion, Greece
    Breast Cancer Res 10:R80. 2008
    ..EGFR and HER2 are expressed in circulating tumor cells, but the activation status of downstream signaling molecules has not yet been reported...
  20. pmc Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients
    Galatea Kallergi
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Voutes, Heraklion, 71110, Greece
    Breast Cancer Res 11:R84. 2009
    ..Since hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) play an important role in angiogenesis and tumor progression, the purpose of the current study was to investigate their expression in CTCs...
  21. pmc Risk factors for nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae: data from a nation-wide surveillance study in Greece
    Ioannis Katsarolis
    4th Dept of Internal Medicine, Athens Medical School, Attikon University General Hospital, Athens, Greece
    BMC Infect Dis 9:120. 2009
    ....
  22. pmc Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria
    Matthew E Falagas
    Alfa Institute of Biomedical Sciences, Athens, Greece
    BMC Infect Dis 5:24. 2005
    ..However, there are already clinical isolates of Gram-negative bacteria that are resistant to all available antibiotics, including polymyxins...
  23. pmc A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group, 55 Lombardou str, 114 74 Athens, Greece
    BMC Cancer 10:633. 2010
    ..To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  24. ncbi request reprint Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans
    G Samonis
    Department of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece
    Med Mycol 44:233-5. 2006
    ..albicans, especially if they received ertapenem. Mice fed regular chow and treated with the study antibiotics or saline did not have Candida in their stools. Candida was not detected in the internal organs of any group of mice...
  25. ncbi request reprint Effects of vancomycin, teicoplanin, linezolid, quinupristin-dalfopristin, and telithromycin on murine gut colonization by Candida albicans
    G Samonis
    Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece
    Med Mycol 44:193-6. 2006
    ..This increase was not statistically significant. Mice fed regular chow treated with the study drugs or saline did not have any yeasts in their stools. Dissemination of Candida was not observed in the visceral organs of any mouse...
  26. ncbi request reprint Docetaxel in the treatment of advanced non-small-cell lung cancer
    Emmanouel Saloustros
    Department of Medical Oncology, University Hospital of Heraklion, Voutes 71110, Heraklion, Crete, Greece
    Expert Rev Anticancer Ther 8:1207-22. 2008
    ..This review article summarizes recent studies of docetaxel as a single agent and in combination regimens with cytotoxic or targeted therapies in the management of patients with advanced NSCLC...
  27. pmc Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
    John Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Breast Cancer Res 8:R36. 2006
    ..To evaluate the incidence of central nervous system (CNS) involvement in patients with breast cancer treated with a taxane-based chemotherapy regimen and to determine predictive factors for CNS relapse...
  28. doi request reprint Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    D Mavroudis
    Department of Medical Oncology, University Hospital of Heraklion, 71110 Heraklion, PO Box 1352, Crete, Greece
    Ann Oncol 21:48-54. 2010
    ..The purpose of this study was to compare docetaxel plus epirubicin versus docetaxel plus capecitabine combinations as front-line treatment in women with advanced breast cancer (ABC)...
  29. ncbi request reprint Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial
    Vassilis Georgoulias
    The Hellenic Oncology Research Group HORG, Athens, Greece
    Lung Cancer 59:57-63. 2008
    ..The DG regimen was associated with a significantly better quality of life. The efficacy of the docetaxel plus gemcitabine combination is superior to single-agent docetaxel in chemonaive patients with advanced NSCLC...
  30. ncbi request reprint Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study
    Nikolaos Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 70:280-4. 2006
    ..A multicenter phase II study was conducted in order to evaluate the efficacy and safety of oxaliplatin as first-line treatment of patients with locally advanced or metastatic carcinoma of the biliary tract...
  31. pmc Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
    J Souglakos
    Department of Medical Oncology, University Hospital of Heraklion, Voutes and Stavrakia, Heraklion, Crete, Greece
    Br J Cancer 101:465-72. 2009
    ..We address the prognostic and predictive value of KRAS, PIK3CA and BRAF mutations for clinical outcomes in response to active agents in the treatment of metastatic colorectal cancer (mCRC)...
  32. doi request reprint Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans
    George Samonis
    Division of Medicine, University of Crete, Crete, Greece
    Mycoses 51:324-7. 2008
    ..However, these increases are not associated with dissemination of the yeast to internal organs. Clinical studies in humans are needed to validate our findings, especially in patients at risk of developing disseminated candidosis...
  33. ncbi request reprint Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition
    Sophia Agelaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Voutes, Greece
    Cancer Biol Ther 8:1470-7. 2009
    ..This is associated with enhanced antitumor effects of gefitinib suggesting a role for EGFR inhibition in caveolin-1 overexpressing breast cancers...
  34. pmc Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
    Christos Emmanouilides
    Department of Medical Oncology, Interbalkan Medical Center, Thessaloniki, Greece
    BMC Cancer 7:91. 2007
    ..To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)...
  35. pmc FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    J Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion, Crete 71110, Greece
    Br J Cancer 94:798-805. 2006
    ..The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature...
  36. doi request reprint Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Ioannis Boukovinas
    Hellenic Oncology Research Group HORG, 55 Lomvardou str, 11740 Athens, Greece
    Cancer Chemother Pharmacol 69:351-6. 2012
    ..To assess the antitumor activity and toxicity of gemcitabine, cisplatin, and docetaxel (GCD) regimen in patients with locally advanced or metastatic urothelial cancer...
  37. pmc Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
    Emmanouil Saloustros
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Breast Cancer Res 13:R60. 2011
    ..Reliable prognostic markers for late disease relapse are not available. In this study we investigated the value of CTC detection during the first five years of follow-up in predicting late disease relapse...
  38. pmc Salmonella enterica pneumonia in a patient with lung cancer
    George Samonis
    Division of Medicine, School of Medicine, The University of Crete, Heraklion, Crete, Greece
    J Clin Microbiol 41:5820-2. 2003
    ..Despite the early administration of appropriate and adequate treatment, the patient died 7 days after the onset of the infection...
  39. ncbi request reprint High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study
    Charalambos Kouroussis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 71110, Crete, Greece
    Lung Cancer 44:363-8. 2004
    ..To determine the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLTs) of the weekly administration of docetaxel and gemcitabine as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC)...
  40. ncbi request reprint A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors
    S Kakolyris
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 63:213-8. 2002
    ..A phase I study was conducted in order to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of their combination in patients with refractory solid tumors...
  41. ncbi request reprint Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours
    N Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Crete, Greece
    Eur J Cancer 38:1992-7. 2002
    ....
  42. ncbi request reprint A dose escalation study of leucovorin (LV) and 48-hour continuous infusion of 5-fluorouracil in combination with cyclophosphamide and vinorelbine in pretreated patients with metastatic breast cancer
    Charalambos Kouroussis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Anticancer Res 24:4217-21. 2004
    ....
  43. doi request reprint Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group
    A G Pallis
    Hellenic Oncology Research Group, Athens, Greece
    Ann Oncol 22:2448-55. 2011
    ..Approximately 50% of newly diagnosed cases of non-small-cell lung cancer (NSCLC) are observed in patients >65 years, while 30%-40% of cases occur in patients >70 years...
  44. ncbi request reprint Effects of erythromycin, clarithromycin, roxithromycin and azithromycin on murine gut colonization by Candida albicans
    G Samonis
    Division of Medicine, The University of Crete, Herkalion, Greece
    Med Mycol 40:139-42. 2002
    ..albicans concentration of the gastrointestinal tract. This increase is not associated with a higher risk of disseminated candidiasis...
  45. doi request reprint A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer
    Athanasios Kotsakis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 68:415-22. 2011
    ..I:12.4-33.5%] were documented. The combination of pemetrexed and docetaxel seems to be an effective regimen in NSCLC with acceptable and manageable toxicity, which merits further investigation...
  46. ncbi request reprint Docetaxel (taxotere) in the treatment of non-small cell lung cancer
    Vassilis Georgoulias
    Medical Oncology, School of Medicine, University of Crete, Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Crete, 711 10 Heraklion, Greece
    Curr Med Chem 9:869-77. 2002
    ..2 months to 10.5 months. Randomized trials revealed that second-line docetaxel confers a survival benefit over either BSC or ifosfamide/vinorelbine in pretreated patients with NSCLC...
  47. ncbi request reprint A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer
    Athanasios Kotsakis
    Hellenic Oncology Research Group HORG, Athens, Greece
    Anticancer Res 30:4335-42. 2010
    ..A retrospective analysis of the sequence administration of these regimens in the first- and second-line setting was performed...
  48. doi request reprint Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Clin Breast Cancer 7:883-9. 2007
    ..The aim of this study was to evaluate the clinical relevance of the simultaneous detection of cytokeratin (CK)-19 messenger RNA (mRNA)- and HER2 mRNA-positive cells in peripheral blood of women with early-stage breast cancer...
  49. doi request reprint Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study
    Athanasios G Pallis
    Hellenic Oncology Research Group HORG, Athens, Greece
    Clin Lung Cancer 12:100-5. 2011
    ..This study evaluates the activity and toxicity of the paclitaxel/carboplatin (PC) doublet versus vinorelbine/carboplatin (VC) doublet as second-line treatment in patients who have advanced non-small-cell lung cancer (NSCLC)...
  50. doi request reprint A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors
    Zacharenia Saridaki
    Department of Medical Oncology, University Hospital of Heraklion, 71110 Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 65:121-8. 2009
    ..To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTDs) of the paclitaxel, gemcitabine, oxaliplatin combination administered biweekly in patients with advanced solid tumors...
  51. ncbi request reprint Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study
    Alexandros Ardavanis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 71110, Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 58:742-8. 2006
    ..To investigate the activity and tolerance of pegylated liposomal doxorubicin in combination with vinorelbine in pretreated patients with metastatic breast cancer...
  52. ncbi request reprint A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer
    Charalambos Kouroussis
    Department of Medical Oncology, School of Medicine, University General Hospital of Heraklion, P O Box 1352, 71110, Heraklion, Crete, Greece
    Anticancer Res 23:785-91. 2003
    ....
  53. ncbi request reprint Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial
    Ioannis Gioulbasanis
    Department of Medical Oncology, University General Hospital of Heraklion, Greece
    Anticancer Res 28:3019-25. 2008
    ..To determine the tolerability and efficacy of the combination of gefitinib with gemcitabine plus vinorelbine in metastatic breast cancer (MBC) patients, pretreated with anthracyclines and taxanes...
  54. doi request reprint Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience
    Athanasios G Pallis
    Hellenic Oncology Research Group HORG, Athens, Greece
    J Thorac Oncol 3:505-10. 2008
    ..Moreover, in clinical practice, > 75% of patients older than 65 years with metastatic NSCLC never receive any kind of chemotherapy...
  55. doi request reprint Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance
    Stella Apostolaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Heraklion, Crete, Greece
    Breast Cancer Res Treat 117:525-34. 2009
    ..0001) and OS (P = 0.003). HER2 mRNA could be a valuable prognostic marker for the detection of CTCs in early breast cancer patients...
  56. doi request reprint Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab
    Aris Polyzos
    Hellenic Oncology Research Group, 55, Lomvardou str, 11470 Athens, Greece
    Cancer Chemother Pharmacol 68:217-23. 2011
    ..Weekly paclitaxel (P) in combination with bevacizumab (B) is an effective regimen as initial treatment of metastatic breast cancer (MBC). We investigated in a phase II study the activity of the same regimen as salvage therapy in MBC...
  57. doi request reprint FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Aristides Polyzos
    Medical Oncology Unit, 1st Propedeutic Clinic, University School of Medicine, Laiko General Hospital of Athens, Athens, Greece
    Breast Cancer Res Treat 119:95-104. 2010
    ....
  58. ncbi request reprint A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer
    Athanasios G Pallis
    Department of Medical Oncology, University Hospital of Heraklion, Greece
    Lung Cancer 52:165-71. 2006
    ..To evaluate the activity and toxicity of the sequential administration of vinorelbine/cisplatin (VC regimen) followed by the docetaxel/gemcitabine (DG regimen) combination in patients with advanced non-small cell lung cancer (NSCLC)...
  59. ncbi request reprint Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status
    Aristea Kalikaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Greece
    Lung Cancer 69:110-5. 2010
    ..Whether EGFR and K-RAS mutations could also predict clinical outcome of non-small cell lung cancer (NSCLC) patients following front-line chemotherapy has not yet been established...
  60. ncbi request reprint Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer
    Sophia Baka
    Hellenic Oncology Research Group HORG, 55 Lomvardou str, 11470, Athens, Greece
    Anticancer Res 30:3031-8. 2010
    ..To compare the efficacy and tolerance of sequential versus alternate front-line administration of cisplatin-etoposide (PE) and topotecan (T) in patients with extensive stage small cell lung cancer (SCLC)...
  61. ncbi request reprint A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors
    Kostas Kalbakis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 62:449-56. 2008
    ....
  62. doi request reprint Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Clin Cancer Res 14:2593-600. 2008
    ..To investigate the prognostic value of the molecular detection of circulating tumor cells (CTCs) using three markers [cytokeratin 19 (CK19), mammaglobin A (MGB1), and HER2] in early breast cancer...
  63. doi request reprint Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen
    Chara Papadaki
    Laboratory of Tumor Cell Biology, School of Medicine, University of Crete, Crete, Greece
    Clin Cancer Res 15:3827-33. 2009
    ..The prognostic and predictive value of tumoral expression of both genes was evaluated in patients with lung adenocarcinoma treated with first-line docetaxel and gemcitabine...
  64. ncbi request reprint Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group
    Michail Ignatiadis
    Department of Medical Oncology, School of Medicine, University of Crete, Greece
    Clin Lung Cancer 7:183-9. 2005
    ..This trial was designed to compare the efficacy and toxicity of sequential versus alternating administration of cisplatin/etoposide and topotecan in patients with previously untreated extensive-stage small-cell lung cancer (SCLC)...
  65. ncbi request reprint Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study
    Stylianos Kakolyris
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Greece
    Lung Cancer 54:347-52. 2006
    ..To evaluate the activity and tolerance of gemcitabine in combination with oxaliplatin (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC)...
  66. ncbi request reprint Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study
    Panagiotis Ziotopoulos
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71100 Heraklion, Crete, Greece
    Lung Cancer 50:115-22. 2005
    ..To evaluate the efficacy and tolerance of the irinotecan plus docetaxel combination in patients with advanced non-small cell lung cancer (NSCLC)...
  67. doi request reprint Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial
    Ourania Katopodis
    Hellenic Oncology Research Group HORG, 55 Lombardou str, 11470 Athens, Greece
    Cancer Chemother Pharmacol 67:361-8. 2011
    ..To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas...
  68. doi request reprint A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract
    Niki Karachaliou
    Hellenic Oncology Research Group, Athens, Greece
    Oncology 78:356-60. 2010
    ..To evaluate the efficacy and tolerability of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11) as first-line treatment of advanced biliary tract cancer...
  69. ncbi request reprint A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors
    John Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Cancer Invest 23:505-10. 2005
    ..To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of L-OHP plus 5-FU and LV in patients with advanced solid malignancies...
  70. doi request reprint A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
    Athanasios G Pallis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 711 10 Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 67:1239-45. 2011
    ..Objective responses were observed in 20.8% of patients with measurable disease. The regimen of metronomic administration and cisplatin is feasible and active in patients with NSCLC...
  71. doi request reprint Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
    Nikolaos Xenidis
    Department of Medical Oncology, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
    Cancer Chemother Pharmacol 68:63-8. 2011
    ..To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer...
  72. ncbi request reprint Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC)
    Charalambos Kouroussis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Am J Clin Oncol 25:627-31. 2002
    ....
  73. ncbi request reprint A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer
    Theodore Giannakakis
    Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
    Anticancer Res 22:3743-8. 2002
    ..To evaluate the efficacy and safety of docetaxel in combination with carboplatin as first-line treatment of patients with inoperable, locally advanced or metastatic non-small cell lung cancer (NSCLC)...
  74. doi request reprint Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study
    Charalambos Kouroussis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Oncology 76:112-7. 2009
    ..The aim of the study was to evaluate the efficacy and safety of temozolomide in pretreated patients with NSCLC...
  75. doi request reprint Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group
    Sofia Agelaki
    Department of Medical Oncology, University General Hospital of Heraklion, GR 711 10 Heraklion, Crete
    Oncology 78:229-36. 2010
    ..However, conflicting results about their equivalence have been reported...
  76. doi request reprint Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer
    Nikolaos Xenidis
    Department of Medical Oncology, University General Hospital, Heraklion, Crete, Greece
    J Clin Oncol 27:2177-84. 2009
    ..To evaluate the prognostic significance of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in peripheral blood of women with early-stage breast cancer after the completion of adjuvant chemotherapy...
  77. ncbi request reprint A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors
    Zacharenia Saridaki
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece
    Oncology 72:45-50. 2007
    ..To determine the dose-limiting toxicities (DLTs) and the maximum-tolerated doses of the paclitaxel, oxaliplatin (LOHP) and capecitabine combination in patients with advanced solid tumors...
  78. doi request reprint Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study
    Athanasios Karampeazis
    Medical Oncology Unit, 417 NIMTS Veterans Hospital, Athens, Greece
    Cancer 119:2754-64. 2013
    ..In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC)...
  79. ncbi request reprint Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials
    Ioannis A Bliziotis
    Alfa Institute of Biomedical Sciences, Athens, Greece
    Mayo Clin Proc 80:1146-56. 2005
    ..To compare the effectiveness and toxicity of ciprofloxacin vs an aminoglycoside, both in combination with a beta-lactam, for the treatment of febrile neutropenia in the inpatient setting...
  80. ncbi request reprint Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro
    John Michalakis
    Department of Biochemistry, School of Medicine, University of Crete, P O Box 2208, 71003, Heraklion, Greece
    Ann Surg Oncol 14:1220-8. 2007
    ..We investigated in vitro the effect of paclitaxel and hyperthermia on cell proliferation, cell cycle kinetics and cell death under conditions resembling those during intraoperative hyperthermic intraperitoneal chemotherapy...
  81. ncbi request reprint A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 71:159-63. 2006
    ..To evaluate the efficacy and tolerance of the docetaxel/gefitinib combination as second-line treatment in patients with advanced pancreatic cancer...
  82. ncbi request reprint Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study
    Ageliki Rapti
    Department of Medical Oncology, University General Hospital of Heraklion, P O Box 1352, 71113 Heraklion, Crete, Greece
    Lung Cancer 49:241-4. 2005
    ..To evaluate the efficacy and toxicity of the gemcitabine plus vinorelbine combination in pretreated patients with small cell lung cancer (SCLC)...
  83. doi request reprint Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study
    Athanasios Karampeazis
    Hellenic Oncology Research Group HORG, 55, Lomvardou str, 11470 Athens, Greece
    Clin Lung Cancer 12:155-60. 2011
    ..This study compared front-line treatment with docetaxel or vinorelbine in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC)...
  84. ncbi request reprint Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Antonia Kalykaki
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Anticancer Res 28:495-500. 2008
    ..The GEMOX regimen has moderate activity in both platinum-sensitive and resistant ovarian cancer and a toxicity profile that can be significant and therefore requires careful monitoring...
  85. ncbi request reprint Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors
    John Souglakos
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Cancer 95:1326-33. 2002
    ..This study investigated the incidence of nonneutropenic infections and/or febrile episodes in patients with solid tumors receiving frontline docetaxel-based chemotherapy...
  86. ncbi request reprint A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer
    Athanasios G Pallis
    Hellenic Oncology Research Group HORG, Athens, Greece
    Lung Cancer 65:187-91. 2009
    ..To compare the efficacy and safety profile of irinotecan (I) versus the combination of irinotecan/gemcitabine (IG) as second-line treatment of patients with extensive stage small-cell lung cancer (SCLC)...
  87. ncbi request reprint A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
    Vasiliki Bozionelou
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Cancer Chemother Pharmacol 64:785-91. 2009
    ..To determine the maximum tolerated doses (MTDs) and dose limiting toxicities (DLTs) of gemcitabine (GEM), docetaxel (DOC) and carboplatin (CARBO) combination...
  88. ncbi request reprint Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients
    Nikos Xenidis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    J Clin Oncol 24:3756-62. 2006
    ..To evaluate the predictive and prognostic value of peripheral blood cytokeratin-19 (CK-19) mRNA-positive cells in axillary lymph node-negative breast cancer patients...
  89. ncbi request reprint Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial
    Vassilis Georgoulias
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, 711 10 Heraklion, Crete, Greece
    J Clin Oncol 23:2937-45. 2005
    ..Therefore, DG could be used in the first-line setting of advanced NSCLC, especially for patients who cannot tolerate cisplatin...
  90. ncbi request reprint Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 711 10, Crete, Greece
    J Clin Oncol 25:5194-202. 2007
    ..To examine the prognostic value of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in early-stage breast cancer patients focusing on clinically relevant subgroups based on estrogen receptor (ER) and HER2 expression...
  91. doi request reprint Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer
    Magdalini Kioulafa
    Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece
    Int J Cancer 125:2887-92. 2009
    ..989-42.454; p=0.004). CST6 promoter methylation status in tumor cells seems to provide important prognostic information in operable breast cancer and merits to be further evaluated and validated in a larger cohort of patients...
  92. ncbi request reprint Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells
    Galatea Kallergi
    Department of Biochemistry, University of Crete Medical School and University Hospital, Heraklion, Greece
    Cell Physiol Biochem 20:977-86. 2007
    ..The results presented here indicate that actin reorganization through FAK/PI3-K/Rac-1 activation operates in various human cancer cell systems supporting a functional role for FAK/PI-3K/Rac1/actin signaling in controlling cell motility...
  93. ncbi request reprint A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer
    Sofia Agelaki
    Department of Medical Oncology, University General Hospital, Heraklion, Greece
    Oncology 66:192-6. 2004
    ..To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer...
  94. ncbi request reprint A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies
    George Samonis
    Department of Internal Medicine, University of Crete, Heraklion, Greece
    Support Care Cancer 21:2521-6. 2013
    ..To study the epidemiology and outcomes of bacteremia in patients with hematologic or solid organ malignancies cared for at the University Hospital of Heraklion, Greece...
  95. ncbi request reprint Fatal Nocardia farcinica bacteremia in a patient with lung cancer
    Athanassia Christidou
    Department of Clinical Bacteriology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece
    Diagn Microbiol Infect Dis 50:135-9. 2004
    ..N. farcinica bacteremia is a life-threatening infection. Because of the actinomycete's highly-resistant antibiotic profile, early identification and antibiotic susceptibility testing are necessary to improve the chances of survival...
  96. doi request reprint Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data
    George Samonis
    Department of Internal Medicine, University Hospital, Heraklion, Crete, Greece
    Scand J Infect Dis 40:414-9. 2008
    ..In line with results of other relevant studies, we documented that a considerable proportion of Candida bloodstream infections were due to non-albicans Candida species...
  97. pmc Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome
    George Samonis
    Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece
    PLoS ONE 7:e37375. 2012
    ..Stenotrophomonas maltophilia is acquiring increasing importance as a nosocomial pathogen...
  98. doi request reprint Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin
    Matthew E Falagas
    Alfa Institute of Biomedical Sciences AIBS, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece
    Int J Antimicrob Agents 35:497-9. 2010
    ..Fosfomycin was inactive against the 166 enterococcal isolates tested. This old antibiotic may deserve consideration for further studies and use in clinical practice, especially for S. aureus (including MRSA) infections...
  99. ncbi request reprint Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials
    George Samonis
    Department of Medicine, University Hospital of Heraklion, Heraklion, Crete, Greece
    Future Microbiol 5:961-70. 2010
    ..The aim of this study was to evaluate the in vitro activity of fosfomycin against Gram-negative nonurinary isolates in a region of Greece where considerable antimicrobial resistance has been detected...
  100. ncbi request reprint Nosocomial infections after off-pump coronary artery bypass surgery: frequency, characteristics, and risk factors
    Evangelos S Rosmarakis
    Alfa Institute of Biomedical Sciences AIBS, Athens, Greece
    Interact Cardiovasc Thorac Surg 6:759-67. 2007
    ..The identification of risk factors for infection in combination with the appropriate evaluation of the increased CRP and procalcitonin values may help clinicians for the early diagnosis of infection after OPCABG...
  101. doi request reprint Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study
    Dimitrios K Matthaiou
    Alfa Institute of Biomedical Sciences, Athens, Greece
    Crit Care Med 36:807-11. 2008
    ..We aimed to investigate the potential risk factors for the isolation of colistin-resistant Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa from hospitalized patients...